BAIYUNSHAN PH: Malic acid sunitinib has received approval for the listing application of chemical raw materials
I'm PortAI, I can summarize articles.
BAIYUNSHAN PH announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Chemical Pharmaceutical Factory recently received the approval notice for the marketing application of Succinic Acid Sunitinib from the National Medical Products Administration. Succinic Acid Sunitinib is a new oral multi-targeted anti-tumor drug primarily used for the treatment of gastrointestinal stromal tumors, advanced renal cell carcinoma, and advanced pancreatic neuroendocrine tumors
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments